达比加群在老年非瓣膜性房颤合并心衰患者中的临床疗效和安全性研究  

Clinical Efficacy and Safety of Dabigatran in Elderly Patients with Non Valvular Atrial Fibrillation and Heart Failure

作　　者：张金鑫 戴红艳[3] 樊纯祯 荣媛媛[3] 管军[5] 

机构地区：[1]大连医科大学,辽宁 大连 [2]青岛市市立医院,山东 青岛 [3]青岛市市立医院保健四科,山东 青岛 [4]青岛大学青岛医学院,山东 青岛 [5]青岛市市立医院心内科,山东 青岛

出　　处：《临床医学进展》2023年第1期662-668,共7页Advances in Clinical Medicine

摘　　要：本研究拟探讨达比加群在老年非瓣膜病性房颤合并心衰患者中的抗凝效果以及安全性,以及达比加群对不同类型、不同程度的心衰患者的抗凝效果。为这类患者优化抗凝药物选择提供临床依据。方法:选择2018年1月~2022年12月在我院门诊或住院部接受长期抗凝治疗的老年NVAF合并心衰的患者207例,分为达比加群组和华法林组。目的:探讨达比加群对高龄无瓣膜房颤伴心力衰竭的长期抗凝药效果及疗效,但其安全性显著高于华法林。This study intends to explore the anticoagulation effect and safety of dabigatran in elderly patients with non valvular atrial fibrillation and heart failure, and the anticoagulation effect of dabigatran in patients with different types and degrees of heart failure to provide clinical basis for optimizing the selection of anticoagulant drugs for such patients. Methods: 207 elderly NVAF patients with heart failure who received long-term anticoagulation treatment in our outpatient or inpatient depart-ment from January 2018 to December 2022 were selected and divided into dabigar group and war-farin group. Objective: To investigate the long-term anticoagulant effect of dabigatran on valveless atrial fibrillation with heart failure in the elderly, but its safety is significantly higher than warfarin.

关 键 词：达比加群 老年非瓣膜病性房颤合并心衰患者 

分 类 号：R54[医药卫生—心血管疾病]